Good morning, Jason Mast here filling in for Ed. Happy turkey week to all. I, for one, have always detested that dry, tasteless bird. (It’s sides and brisket for me, followed by pecan pie.) So in their interest, I leave you with this story, from 2018, about the Ozark turkeys that fell from the sky. A trajectory not unlike Novo Nordisk’s stock, after today’s news. …
Novo Nordisk’s weight loss drug semaglutide failed to slow the progression of Alzheimer’s disease in two large trials, STAT reports. The results will, for now, quiet excitement around a darkhorse theory for treating Alzheimer’s that had percolated over the last few years, based on retrospective studies that suggested patients taking the drug had lower risk of dementia, possibly because it dampened inflammation. Executives at Novo, which is down 10% today, had long warned the studies were risky.
Bayer said its experimental drug asundexian slashed the risk of recurrent stroke in a Phase 3 study, Endpoints News relays. Asundexian is a factor XIa inhibitor, a class of drugs that has had mixed results in clinical trials so far. Bristol Myers Squibb and Johnson & Johnson recently cut their own Phase 3 trial of a XIa inhibitor in a different indication, saying it was unlikely to succeed. A Phase 3 for stroke recurrence for that drug is still underway. Bayer has yet to release detailed data.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.